Jin Yang Pharmaceutical Co., Ltd. (007370.KQ) Stock

007370.KQ logo

Jin Yang Pharmaceutical Co., Ltd.

007370.KQSouth Korea
Healthcare

Company profile

Jin Yang Pharmaceutical reported revenue of 120.69 billion KRW for fiscal year 2025, up 6.5% from fiscal year 2024, and net income of 22.29 billion KRW. That is a net profit margin of 18.5% for fiscal year 2025. Our analysis of its filings shows revenue growing from 93.71 billion KRW in fiscal year 2023 to 120.69 billion KRW in fiscal year 2025, 13.5% a year on average.

What stands out

  • Its net profit margin over the last four reported quarters was 18.3%, against a median of -1.1% for 6 listed companies of similar size in its industry.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Jin Yang Pharmaceutical Co., Ltd.

Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports its products. Jin Yang Pharmaceutical Co., Ltd. was founded in 1971 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Jin Yang Pharmaceutical Co., Ltd.6.40%
  • Jae-Jun Choi3.896 %3.90%
  • Yoon-Hwan Choi2.681 %2.68%
  • Su-ja Han1.698 %1.70%
  • Joong-ho Choi0.9438 %0.94%

Share of the company, as of September 25, 2026

Leadership

  • Jae-Joon Choi — CEO & Representative Director, 55
  • Choi Yoon Hwan — Founder, President & Chairman, 88

How much revenue does Jin Yang Pharmaceutical make?

Jin Yang Pharmaceutical reported 120.69 billion KRW in revenue for fiscal year 2025, up 6.5% from 113.33 billion KRW in fiscal year 2024.

What companies are similar to Jin Yang Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Ctcbio Inc. (060590.KQ), Ildong Holdings Co., Ltd. (000230.KS), Icure Pharmaceutical Incorporation (175250.KQ), Myungmoon Pharm co.,Ltd (017180.KS).

How does Jin Yang Pharmaceutical's profit margin compare with similar companies?

Net profit margin over the last four reported quarters: Jin Yang Pharmaceutical, 18.3%; Ctcbio Inc. (060590.KQ), 5.7%; Ildong Holdings Co., Ltd. (000230.KS), 3.6%; Icure Pharmaceutical Incorporation (175250.KQ), -18.9%; Myungmoon Pharm co.,Ltd (017180.KS), -0.8%; Bcworld Pharm. Co., Ltd. (200780.KQ), -3.6%; Korea Arlico Pharm Co.,Ltd. (260660.KQ), -1.5%.

How has Jin Yang Pharmaceutical's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 62.84 billion KRW; FY2022, 76.26 billion KRW; FY2023, 93.71 billion KRW; FY2024, 113.33 billion KRW; FY2025, 120.69 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersSeoul, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Jinyang Pharm Building, Seoul
Phone
82 2 3470 0300
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Jin Yang Pharmaceutical Co., Ltd. (007370.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/007370.KQ

LinkedInLinkedInXXYouTubeYouTube